Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JAPMS to Establish Working Group on Improvement of Drug Distribution
June 6, 2012
- JMA Board Members Caution Against Rush to Introduce Cost-Effective Assessment: Dr Suzuki
June 5, 2012
- MREAC to Release Passing Scores for MR Exam Starting This Year
June 4, 2012
- JMA Requests FPMAJ, JPMA to Set Up Nursery Care Facilities for Lectures
June 4, 2012
- Head of Wholesale Industry FTC Calls for Compliance with Competition Code as Violation Cases Increase to Five
May 29, 2012
- Capital Investment Needed for Bar Code Labeling Estimated at About 700 Million Yen Per Drug Maker: JPWA, JPMA Survey
May 28, 2012
- Three Head Office-Level Violations of Fair Competition Code in FY2011: Drug Marketing Industry’s FTC
May 23, 2012
- Greater Centralization, Clarity Needed in Formulating Medical Innovation Policy: Dr Teshirogi of JPMA
May 21, 2012
- Pharma Industry FTC Implements New GL on Restriction of Business Entertaining Rules, Without Acceptance of CAA
May 21, 2012
- JPMA Approves MTPC’s Re-Enrollment 16 Months after Quitting
May 18, 2012
- “Cost-Effective Assessment Inhibits Innovation”: FPMAJ Chairman Naito
May 18, 2012
- Interview with Alfonso G. Zulueta of PhRMA
May 14, 2012
- Greater Concern than Hope about HTA: Mr Zulueta of PhRMA
May 14, 2012
- Participation in TPP to Lead to Higher NHI Prices: JMA VP Nakagawa
May 10, 2012
- 87% of Respondents Affirmative on Introduction of Medicoeconomic Assessment: JAPhMed Survey
May 9, 2012
- JPMA Compiles Manual for Providing Drugs in the Event of Disasters
April 24, 2012
- JPMA Opposes Haste Adoption of Cost-Effective HTA
April 20, 2012
- National Centers for Advanced and Specialized Medical Cares to Join NHO, JLHWO Hospitals in Joint Purchasing
April 20, 2012
- Degree of Drug Contribution Increased Most for HIV and AIDS: JHSF Survey
April 13, 2012
- MREAC Seeks to Contact 70 People Who Passed MR Exam through “Transitional Measure”
April 10, 2012
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…